Patents by Inventor Penglie Zhang

Penglie Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Piperidine derivatives and methods of use
    Publication number: 20070093467
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: October 11, 2006
    Publication date: April 26, 2007
    Applicant: ChemoCentryx, Inc.
    Inventors: Penglie Zhang, Andrew Pennell, Wei Chen, Kevin Greenman, Edward Sullivan, Lianfa Li
  • Piperidine derivatives and methods of use
    Publication number: 20070088036
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: October 11, 2006
    Publication date: April 19, 2007
    Applicant: ChemoCentryx, Inc.
    Inventors: Penglie Zhang, Andrew Pennell, Wei Chen, Kevin Greenman, Lianfa Li, Edward Sullivan
  • Monocyclic and bicyclic compounds and methods of use
    Publication number: 20070066583
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: August 14, 2006
    Publication date: March 22, 2007
    Applicant: ChemoCentryx, Inc.
    Inventors: Penglie Zhang, Andrew Pennell, John J. Wright, Lianfa Li, Edward Sullivan, Wei Chen, Kevin Lloyd Greenman
  • Benzamides and related inhibitors of factor Xa
    Publication number: 20070021472
    Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Application
    Filed: July 17, 2006
    Publication date: January 25, 2007
    Inventors: Bing-Yan Zhu, Penglie Zhang, Lingyan Wang, Wenrong Huang, Erick Goldman, Wenhao Li, Jingmei Zuckett, Yonghong Song, Robert Scarborough
  • Azaindazole compounds and methods of use
    Publication number: 20070010523
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: June 22, 2006
    Publication date: January 11, 2007
    Applicant: ChemoCentryx, Inc.
    Inventors: Penglie Zhang, Andrew Pennell, John J. Wright, Wei Chen, Manmohan Leleti, Matthew Ronsheim
  • Azaindazole compounds and methods of use
    Publication number: 20070010524
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: June 22, 2006
    Publication date: January 11, 2007
    Applicant: ChemoCentryx, Inc.
    Inventors: Penglie Zhang, Andrew Pennell, John J. Wright, Wei Chen, Manmohan Leleti, Yandong Li, Lianfa Li, Yuan Xu
  • Benzamides and related inhibitors of factor Xa
    Publication number: 20060241153
    Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Application
    Filed: May 26, 2006
    Publication date: October 26, 2006
    Inventors: Bing-Yan Zhu, Penglie Zhang, Lingyan Wang, Wenrong Huang, Erick Goldman, Wenhao Li, Jingmei Zuckett, Yonghong Song, Robert Scarborough
  • Substituted piperazines
    Publication number: 20060106218
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: December 8, 2004
    Publication date: May 18, 2006
    Applicant: ChemoCentryx, Inc.
    Inventors: Andrew Pennell, James Aggen, J.J. Wright, Subhabrata Sen, Brian McMaster, Daniel Dairaghi, Wei Chen, Penglie Zhang
  • Bicyclic and bridged nitrogen heterocycles
    Publication number: 20060074121
    Abstract: Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.
    Type: Application
    Filed: September 1, 2005
    Publication date: April 6, 2006
    Applicant: ChemoCentryx, Inc.
    Inventors: Wei Chen, Penglie Zhang, James Aggen, Daniel Dairaghi, Andrew Pennell, Subhabrata Sen, J.J. Wright
  • Thioether-substituted benzamides as inhibitors of Factor Xa
    Patent number: 7022695
    Abstract: Thioether-substituted benzamide compounds having the formula: are provided that exhibit exceptionally strong inhibition of Factor Xa in combination with weak hERG binding.
    Type: Grant
    Filed: October 5, 2004
    Date of Patent: April 4, 2006
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Erick A. Goldman, Wenrong Huang, Penglie Zhang
  • Benzamides and related inhibitors of factor Xa
    Publication number: 20060020039
    Abstract: Novel benzamide compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Application
    Filed: January 14, 2005
    Publication date: January 26, 2006
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Penglie Zhang, Lingyan Wang, Wenrong Huang, Erick Goldman, Wenhao Li, Jingmei Zuckett, Yonghong Song, Robert Scarborough
  • Benzamides and related inhibitors of factor Xa
    Publication number: 20050261346
    Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Application
    Filed: September 15, 2004
    Publication date: November 24, 2005
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Penglie Zhang, Lingyan Wang, Wenrong Huang, Erick Goldman, Wenhao Li, Jingmei Zuckett, Yonghong Song, Robert Scarborough
  • Substituted piperazines
    Publication number: 20050256130
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: November 1, 2004
    Publication date: November 17, 2005
    Applicant: ChemoCentryx, Inc.
    Inventors: Andrew Pennell, James Aggen, J.J. Wright, Subhabrata Sen, Brian McMaster, Daniel Dairaghi, Wei Chen, Penglie Zhang
  • Bicyclic and bridged nitrogen heterocycles
    Publication number: 20050234034
    Abstract: Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.
    Type: Application
    Filed: March 2, 2005
    Publication date: October 20, 2005
    Applicant: ChemoCentryx, Inc.
    Inventors: Andrew Pennell, James Aggen, J.J. Wright, Subhabrata Sen, Wei Chen, Daniel Dairaghi, Penglie Zhang
  • Thioether-substituted benzamides as inhibitors of factor Xa
    Publication number: 20050154204
    Abstract: Thioether-substituted benzamide compounds having the formula: are provided that exhibit exceptionally strong inhibition of Factor Xa in combination with weak hERG binding.
    Type: Application
    Filed: October 5, 2004
    Publication date: July 14, 2005
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Erick Goldman, Wenrong Huang, Penglie Zhang
  • Benzamides and related inhibitors of factor Xa
    Patent number: 6844367
    Abstract: Novel benzamide compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: September 15, 2000
    Date of Patent: January 18, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Penglie Zhang, Lingyan Wang, Wenrong Huang, Erick A. Goldman, Wenhao Li, Jingmei Zuckett, Yonghong Song, Robert M. Scarborough
  • Benzamides and related inhibitors of factor Xa
    Patent number: 6835739
    Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: October 15, 2003
    Date of Patent: December 28, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Penglie Zhang, Lingyan Wang, Wenrong Huang, Erick A. Goldman, Wenhao Li, Jingmei Zuckett, Yonghong Song, Robert M. Scarborough
  • Benzamides and related inhibitors of factor Xa
    Publication number: 20040097561
    Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Application
    Filed: October 15, 2003
    Publication date: May 20, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Penglie Zhang, Lingyan Wang, Wenrong Huang, Erick A. Goldman, Wenhao Li, Jingmei Zuckett, Yonghong Song, Robert M. Scarborough
  • Piperazine based inhibitors of factor xa
    Publication number: 20040082786
    Abstract: Novel compounds of the general formulae (I) or (II), including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and the compositions are useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis.
    Type: Application
    Filed: October 16, 2003
    Publication date: April 29, 2004
    Inventors: Bing-Yan Zhu, Zhaozhong Jon Jia, Penglie Zhang, Wenrong Huang, Yanhong Wu, Jingmei Fan Zuckett, Erik A. Goldman, Lingyan Wang, Younghong Song, Robert M. Scarborough
  • Quaternary amidino based inhibitors of factor xa
    Publication number: 20040077690
    Abstract: Novel quaternary amidino-containing compounds of the general formulae (I), (II), (III), (IV), (V) and (VI): including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and the compositions are useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis.
    Type: Application
    Filed: October 16, 2003
    Publication date: April 22, 2004
    Inventors: Bing-Yan Zhu, Wenrong Huang, Penglie Zhang, Zhaozhong Jon Jia, Liang Bao, Yanhong Wu, Robert M. Scarborough